IL263979B2 - Viruses with an envelope resistant to the immune system for cancer treatment - Google Patents

Viruses with an envelope resistant to the immune system for cancer treatment

Info

Publication number
IL263979B2
IL263979B2 IL263979A IL26397918A IL263979B2 IL 263979 B2 IL263979 B2 IL 263979B2 IL 263979 A IL263979 A IL 263979A IL 26397918 A IL26397918 A IL 26397918A IL 263979 B2 IL263979 B2 IL 263979B2
Authority
IL
Israel
Prior art keywords
protein
sequence
virus
peptide
seq
Prior art date
Application number
IL263979A
Other languages
English (en)
Hebrew (he)
Other versions
IL263979B1 (en
IL263979A (en
Original Assignee
Wellstat Immuno Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Immuno Therapeutics Llc filed Critical Wellstat Immuno Therapeutics Llc
Publication of IL263979A publication Critical patent/IL263979A/en
Publication of IL263979B1 publication Critical patent/IL263979B1/en
Publication of IL263979B2 publication Critical patent/IL263979B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL263979A 2017-05-10 2018-05-10 Viruses with an envelope resistant to the immune system for cancer treatment IL263979B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762504120P 2017-05-10 2017-05-10
PCT/US2018/032018 WO2018209052A1 (en) 2017-05-10 2018-05-10 Enveloped virus resistant to complement inactivation for the treatment of cancer

Publications (3)

Publication Number Publication Date
IL263979A IL263979A (en) 2019-02-28
IL263979B1 IL263979B1 (en) 2023-05-01
IL263979B2 true IL263979B2 (en) 2023-09-01

Family

ID=64105722

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263979A IL263979B2 (en) 2017-05-10 2018-05-10 Viruses with an envelope resistant to the immune system for cancer treatment

Country Status (12)

Country Link
US (2) US11274141B2 (OSRAM)
EP (1) EP3621635A4 (OSRAM)
JP (1) JP7161940B2 (OSRAM)
KR (3) KR20250118857A (OSRAM)
CN (1) CN109414483B (OSRAM)
AU (1) AU2018265258B2 (OSRAM)
BR (1) BR112018075281A2 (OSRAM)
CA (1) CA3026892A1 (OSRAM)
IL (1) IL263979B2 (OSRAM)
MX (1) MX2018015599A (OSRAM)
WO (1) WO2018209052A1 (OSRAM)
ZA (1) ZA201808040B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN112759654A (zh) * 2019-11-06 2021-05-07 深圳普菲科生命科技有限公司 一种病毒囊膜蛋白装配系统及其方法和应用
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US20240067936A1 (en) * 2021-02-26 2024-02-29 Sillajen, Inc. Oncolytic virus and uses thereof
CN113736810B (zh) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 构建体、载体、蛋白、细胞、制备方法、产品及应用
KR20240003051A (ko) * 2022-06-29 2024-01-08 신라젠(주) Cd55 및 cd59를 동시 발현하는 항암 바이러스
JP2025531806A (ja) * 2022-09-07 2025-09-25 シルラジェン，インコーポレイテッド 抗癌ウイルスの新規用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008061539A (ja) * 2006-09-05 2008-03-21 Osaka Univ ヒト補体制御因子発現遺伝子およびその利用
CA2678774A1 (en) * 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
WO2016164305A1 (en) * 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
WO2016174407A1 (en) * 2015-04-27 2016-11-03 Ucl Business Plc Nucleic acid construct for expressing more than one chimeric antigen receptor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
EP1486211B1 (en) 1993-04-30 2008-10-22 Wellstat Biologics Corporation Compositions for treating cancer using viruses
JPH10313865A (ja) * 1997-05-15 1998-12-02 Deinabetsuku Kenkyusho:Kk ヒト補体制御因子が呈示されたベクター
WO1999027121A1 (en) 1997-11-21 1999-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Development of viruses resistant to inactivation by the human complement system
NZ505312A (en) 1997-12-22 2003-01-31 Univ Tennesse Res Corp Recombinant Vesicular Stomatitis virus comprising a heterologous F protein (Paramyxovirus strain SV5) and CD4 antireceptor protein
WO1999051625A2 (en) * 1998-04-02 1999-10-14 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
CA2370187C (en) 1999-04-15 2011-08-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
DK1569685T3 (da) * 2002-11-15 2012-11-12 Univ Colorado Regents Komplementmodulatorer rettet mod komplementreceptor-2
JP4956427B2 (ja) 2004-07-21 2012-06-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド レンチウイルスベクターおよびその使用
CA2676090A1 (en) 2007-02-06 2008-10-02 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
US20140206850A1 (en) 2011-04-29 2014-07-24 Keygene N.V. Glyphosate resistance enhancement
US9228003B2 (en) 2011-05-05 2016-01-05 Wellstat Immuno Therapeutics, Llc Complement factor B analogs and their uses
WO2013082563A1 (en) * 2011-12-01 2013-06-06 Protevobio, Inc. Protein inhibitors to complement and vegf pathways and methods of use thereof
LT3129470T (lt) * 2014-04-07 2021-07-12 Novartis Ag Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
CN107708741A (zh) 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
US20190282640A1 (en) 2016-05-19 2019-09-19 Turnstone Limited Partnership Pseudotyped oncolytic rhabdoviruses and their use in combination therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008061539A (ja) * 2006-09-05 2008-03-21 Osaka Univ ヒト補体制御因子発現遺伝子およびその利用
CA2678774A1 (en) * 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
WO2016164305A1 (en) * 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof
WO2016174407A1 (en) * 2015-04-27 2016-11-03 Ucl Business Plc Nucleic acid construct for expressing more than one chimeric antigen receptor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN, WEN-TING, ET AL., PROTEOMICS ANALYSIS OF THE DF-1 CHICKEN FIBROBLASTS INFECTED WITH AVIAN REOVIRUS STRAIN S1133., 25 March 2014 (2014-03-25) *
FAJARDO, CARLOS ALBERTO, ET AL., ONCOLYTIC ADENOVIRAL DELIVERY OF AN EGFR-TARGETING T-CELL ENGAGER IMPROVES ANTITUMOR EFFICACY., 30 April 2017 (2017-04-30) *
GUIBINGA, GHIABE H., AND THEODORE FRIEDMANN., BACULOVIRUS GP64-PSEUDOTYPED HIV-BASED LENTIVIRUS VECTORS ARE STABILIZED AGAINST COMPLEMENT INACTIVATION BY CODISPLAY OF DECAY ACCELERATING FACTOR (DAF) OR OF A GP64–DAF FUSION PROTEIN., 30 April 2005 (2005-04-30) *
SPITZER, DIRK, HANSJORG HAUSER, AND DAGMAR WIRTH., COMPLEMENT-PROTECTED AMPHOTROPIC RETROVIRUSES FROM MURINE PACKAGING CELLS., 31 December 1999 (1999-12-31) *
ZAMARIN, DMITRIY, AND PETER PALESE., ONCOLYTIC NEWCASTLE DISEASE VIRUS FOR CANCER THERAPY: OLD CHALLENGES AND NEW DIRECTIONS., 6 March 2012 (2012-03-06) *

Also Published As

Publication number Publication date
KR102662049B1 (ko) 2024-05-23
EP3621635A1 (en) 2020-03-18
KR20250118857A (ko) 2025-08-06
EP3621635A4 (en) 2021-02-24
BR112018075281A2 (pt) 2020-02-11
US20220169701A1 (en) 2022-06-02
AU2018265258B2 (en) 2023-01-05
US20190194292A1 (en) 2019-06-27
CN109414483B (zh) 2025-10-24
CN109414483A (zh) 2019-03-01
AU2018265258A1 (en) 2019-01-17
JP7161940B2 (ja) 2022-10-27
RU2018146446A3 (OSRAM) 2021-09-10
IL263979B1 (en) 2023-05-01
RU2018146446A (ru) 2021-06-10
ZA201808040B (en) 2019-09-25
WO2018209052A1 (en) 2018-11-15
MX2018015599A (es) 2019-05-16
KR20240073085A (ko) 2024-05-24
US11274141B2 (en) 2022-03-15
KR102839445B1 (ko) 2025-07-28
JP2020519230A (ja) 2020-07-02
CA3026892A1 (en) 2018-11-15
KR20200005721A (ko) 2020-01-16
IL263979A (en) 2019-02-28

Similar Documents

Publication Publication Date Title
IL263979B2 (en) Viruses with an envelope resistant to the immune system for cancer treatment
Ortiz et al. New gene therapy strategies for cancer treatment: a review of recent patents
US20230364263A1 (en) Synthetic adenoviruses targeting bone tissue and uses thereof
JP2018537089A5 (OSRAM)
Xu et al. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment
JPWO2019152692A5 (OSRAM)
JP7381604B2 (ja) 癌を治療するための多価ｐｄ－ｌ１結合化合物
WO2014202977A1 (en) Vaccinia virus for gene-directed enzyme prodrug therapy
Wang et al. Current status of gene therapy for hepatocellular carcinoma, with a focus on gene delivery approaches
KR20240022572A (ko) Tnfsf-l 융합 단백질 및 그의 용도
Bhattacharya Current Views on Oncolytic Adenoviruses for Cancer Therapy
RU2816646C2 (ru) Мультивалентные pd-l1-связывающие соединения для лечения злокачественных новообразований
JP2007514429A (ja) 細胞表面に連結され得る物質を連結するためのアダプター
US20230364222A1 (en) Recombinant viruses, surface-engineered delivery systems and related methods
WO2024194186A1 (en) Fusion protein for localized activation of t-cells
HK40062457A (en) Multivalent pd-l1 binding compounds for treating cancer
NZ748798A (en) Enveloped virus resistant to complement inactivation for the treatment of cancer
US20180105802A1 (en) Viral Targeting with Knottins
Nakamura et al. Engineering oncolytic measles viruses for targeted cancer therapy
WO2022049002A1 (en) Peptivax therapy
Muik et al. Oncolytic virotherapy of glioma: what does it need to make it work?
BR112021021683B1 (pt) Compostos multivalentes de ligação a pd-l1 para tratar câncer, composição farmacêutica e uso relacionados
Muik et al. ial R e p o rt
Adeno-Associated et al. Gene Therapy of Cancer
Spencer et al. 786. New Pancreatic Carcinoma Model for Studying Oncolytic Adenoviruses in the Permissive Syrian Hamster